XOMA Royalty Corp XOMA.OQ reported a quarterly adjusted loss of $1.59 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -60 cents. The mean expectation of three analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -66 cents to -32 cents per share.
Revenue rose 767.1% to $7.20 million from a year ago; analysts expected $6.49 million.
XOMA Royalty Corp's reported EPS for the quarter was a loss of $1.59.
The company reported a quarterly loss of $18.61 million.
XOMA Royalty Corp shares had risen by 22.6% this quarter and gained 75.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 28.9% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for XOMA Royalty Corp is 83.00
This summary was machine generated from LSEG data November 7 at 02:38 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.44 | -1.59 | Missed |
Jun. 30 2024 | -0.27 | 0.84 | Beat |
Mar. 31 2024 | -0.81 | -0.86 | Missed |
Dec. 31 2023 | -0.36 | -0.49 | Missed |
Comments